Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34871741)
Watch
English
New drugs for breast cancer
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
New drugs for breast cancer.
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
author name string
Ian E Smith
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
language of work or name
English
0 references
publication date
1 September 2002
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
volume
360
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
page(s)
790-792
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
issue
9335
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
cites work
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Should bisphosphonates be the treatment of choice for metastatic bone disease?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Reduction in new metastases in breast cancer with adjuvant clodronate treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909903-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(02)09903-8
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
PubMed ID
12241842
1 reference
stated in
Europe PubMed Central
PubMed ID
12241842
retrieved
5 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit